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Abstract In spite of almost complete eradication, polio-
myelitis continues to be a global threat even in non-
endemic countries due to the ever-increasing international
travel activities. Health care workers are at a special risk in
acquiring pathogens from travelers returning from endemic
countries. Polio vaccines are fairly well accepted through-
out the German population. Yet, laboratory controls for
successful immunization are carried out only sporadically
in the general population, and not even the medical staV are
routinely tested for polio immunity. The present study was
initiated in order to assess the immunity status of young
people at the very beginning of their career in clinical med-
icine. Within their Wrst clinical semester, all students are
supposed to undergo an obligatory health check in our
Occupational Medicine Unit. A blood sample is taken and
sent under a personal code to our diagnostic laboratories for
virus serology, and for cryoconservation of residual serum,
if available. Within the periods 2004–2006 and 2008–2010,
we analyzed sera from 424 and 427 individuals, respec-
tively, for anti-polio types 1, 2, 3 antibodies by a microneu-
tralization assay. In the latest study period, there was a
slight increase in the rate of fully protected persons: 63.9 %
triple-seropositivity versus 57.1 % in the period 2004–
2006. By the end of the second clinical semester, students
with low or negative antibody levels (1:<10) were
informed, and a (booster) vaccination was recommended.
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Introduction
The progress in eradicating poliomyelitis by vaccination
programs has been accompanied by a series of cumbersome
setbacks. Wild-type polioviruses types 1 and 3 (WPV) are
repeatedly imported from endemic regions into polio-free
countries [1]. A large outbreak in Tajikistan in 2010 [2] as
well as a recent cluster in China in 2011 [3] demonstrates
that poliomyelitis still is more than a merely theoretical
problem for global health. A further problem is the emer-
gence of mutant poliovirus strains [4, 5] originating from
the live, attenuated oral poliovirus vaccine (OPV), termed
vaccine-derived polioviruses (VDPV). For these reasons,
health authorities are anxious to keep population immunity
at high levels.
As for Germany, a large survey conducted in 1997/1998
covering all age classes and all federal states [6] had
revealed a suYciently high rate of seropositivity against all
three types of polioviruses (85 %). It was, therefore, some-
what disappointing when 7 years later (2005) within a
cohort of medical students at the University of Frankfurt/
Main, only 68 % were found to be completely protected
against poliomyelitis [7].
Having concurrently observed a low immunity rate
among our patients at the Bonn University Clinics, we
started an antibody screening with our medical students.
Our Wrst results in 2003 were alarming so that we decided
to continue the project with a systematic evaluation of the
results from 2004 onwards. The study was designed in a
way that allowed the individual students to easily get infor-
mation about a potential lack of immunity.
M. Külshammer · U. Winke · M. Frank · U. Skali-Lami · 
J. F. Drexler · A. M. Eis-Hübinger · B. Matz (&)
Institute of Virology, University of Bonn Medical Centre, 
Sigmund-Freud-Str. 25, 53105 Bonn, Germany
e-mail: bertfried.matz@ukb.uni-bonn.de
H. Steudel · G. Schilling
Unit of Occupational Medicine, University of Bonn Medical 
Centre, Sigmund-Freud-Str. 25, 53105 Bonn, Germany123
64 Med Microbiol Immunol (2013) 202:63–65Subjects
A semi-anonymous serological survey among medical stu-
dents was conducted in the following way: Prior to their
training in clinical medicine, all students must undergo a
medical examination at our Unit for Occupational Medi-
cine. A blood sample was taken and sent under a personal
code to our diagnostic laboratories for mandatory HBV and
HCV testing and HIV serology on a voluntary basis. Resid-
ual serum samples were stored frozen. For our study, a list
with personal codes of students in their second clinical
semester was transmitted to the laboratory. Whenever
available, the corresponding frozen sera were thawed and
analyzed for poliovirus antibodies. In total, 424 sera avail-
able in the Wrst period (2004–2006) and 427 sera from the
second period (2008–2010) could be analyzed in our study.
A list with the codes of all those individuals with a low
antibody titer (1:<10) was displayed on our notice board.
Methods
Antibodies against poliovirus types 1, 2, and 3 were ana-
lyzed by a manual microneutralization assay essentially as
described earlier for an automated assay [8, 9], using Afri-
can green monkey kidney cell line VERO in 96-well micro-
titer plates (50,000 cells per well) and Sabin vaccine virus
strains at a challenge dose of 100 TCID50 per well. After
3 days of incubation at 37 °C in a 6 % CO2 atmosphere,
cytopathic eVects were monitored by inverse light micros-
copy. A titer below 1:10 was considered as potentially non-
protective.
Results
In the Wrst study period (2004–2006), sera from 424 medi-
cal students were tested for neutralizing antibodies against
the three poliovirus types. Anti-poliovirus type 1 antibodies
were found at titers of 1:10 or higher in 355 samples
(83.7 %), whereas 69 sera (16.3 %) failed to neutralize at
the 1:10 dilution. With poliovirus type 2, the situation was
quite similar: 384 sera (90.6 %) were reactive at 1:10 or
higher dilutions, and 40 samples (9.4 %) were negative at
that dilution. Immunity against type 3 was present (1:10 or
above) only in 265 subjects (62.5 %), and low or absent
(1:<10) in as many as 159 students (37.5 %).
Evaluation of the data from the second study period
(2008–2010) yielded a slight improvement with regard to
the poliovirus type 3 immune status, while the type 1 and
type 2 immunity rates remained largely unchanged. Out of
427 sera, 362 (84.8 %), 380 (89.0 %), and 290 (67.9 %) had
titers (1:10 or more) against poliovirus type 1, type 2, and
type 3, respectively. At the 1:10 dilution, 65 sera (15.2 %)
failed to neutralize type 1, 47 (11.0 %) failed to neutralize
type 2, and 137 (32.1 %) were negative with type 3
(Table 1).
Evaluation of the above data revealed that the rate of stu-
dents protected against all three serotypes increased from
57.1 % (2004–2006) to 63.9 % (2008–2010). A detailed
view of the various combinations of immunity gaps against
the three virus types is given in Table 1.
Discussion
According to the strategic plan of the Global Polio Eradica-
tion Initiative (GPEI), transmission of WPV shall be
stopped by the end of 2012 [10]. A high vaccination cover-
age is a crucial prerequisite for this goal. With an estimated
coverage of 96 %, the European region holds one of the
highest polio vaccination rates worldwide. The results of
our seroprevalence study conWrm this estimation, as 94 %
of our students were antibody positive for at least one of the
three poliovirus types (Table 1). One must assume that vir-
tually all of the seropositivities were vaccine-derived rather
than acquired by contact with WPV.
Although there had been no outbreak of poliomyelitis in
Germany for more than a decade, the results of our study
give cause for concern. Low or even unmeasurable anti-
body levels in vaccinated persons may well suYce to
protect against disease, but nonetheless, infection with
WPV or VDPV and excretion of infectious virus is possible
[11]. It is, therefore, highly advisable to strictly follow the
Table 1 Poliovirus immunity status of medical students
Study period
2004–2006 2008–2010
Number of subjects 424 427
Unprotected against
Serotype 1 69 (16.3 %) 65 (15.2 %)
Serotype 2 40 (9.4 %) 47 (11.0 %)
Serotype 3 159 (37.5 %) 137 (32.1 %)
Serotype 1 only 18 (4.2 %) 12 (2.8 %)
Serotype 2 only 2 (0.5 %) 3 (0.7 %)
Serotype 3 only 97 (22.9 %) 71 (16.6 %)
Serotypes 1 + 2 3 (0.7 %) 2 (0.5 %)
Serotypes 1 + 3 27 (6.4 %) 24 (5.6 %)
Serotypes 2 + 3 14 (3.3 %) 15 (3.5 %)
Serotypes 1 + 2 + 3 21 (5.0 %) 27 (6.3 %)
Unprotected against one, 
two, or all serotypes
182 (42.9 %) 154 (36.1 %)
Protected against at least 
one serotype
403 (95.0 %) 400 (93.7 %)
Protected against all serotypes 242 (57.1 %) 273 (63.9 %)123
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tion in Germany (STIKO) in administering a booster vacci-
nation (with or without prior immune status control) to
health care workers, especially to laboratory personnel han-
dling stool and other potentially infectious specimens [12].
We are fairly certain that the poliomyelitis immunity status
in medical students at Bonn University or at Frankfurt
(Main) University [7] is at best representative for the gen-
eral population in Germany, since future physicians are
rarely belonging to vaccination-opposing groups.
In conclusion, there is surely a moderate improvement
with regard to the poliovirus type 3 immunity in our study
cohort over half a decade, but the data strongly underline
the warnings by the German health authorities concerning
possible importations of polioviruses [13].
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